Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Iradimed is a medical devices business based in the US. Iradimed shares (IRMD) are listed on the NASDAQ and all prices are listed in US Dollars. Iradimed employs 110 staff and has a trailing 12-month revenue of around $50.3 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $36.30 |
|---|---|
| 52-week range | $26.00 - $55.92 |
| 50-day moving average | $29.57 |
| 200-day moving average | $32.73 |
| Wall St. target price | $45.50 |
| PE ratio | 36.274 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.04 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $36.3 from 2023-01-27
| 1 week (2023-01-19) | N/A |
|---|---|
| 1 month (2022-12-30) | 28.31% |
| 3 months (2022-10-28) | 21.57% |
| 6 months (2022-07-29) | -14.08% |
| 1 year (2022-01-28) | -2.42% |
|---|---|
| 2 years (2021-01-29) | 46.73% |
| 3 years (2020-01-30) | 40.43% |
| 5 years (2018-01-30) | 151.21% |
Valuing Iradimed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Iradimed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Iradimed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Iradimed shares trade at around 36x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Iradimed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Iradimed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Iradimed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.2 million.
The EBITDA is a measure of a Iradimed's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $50.3 million |
|---|---|
| Operating margin TTM | 28.79% |
| Gross profit TTM | $32 million |
| Return on assets TTM | 11.46% |
| Return on equity TTM | 18.96% |
| Profit margin | 25.93% |
| Book value | $5.55 |
| Market capitalisation | $474.1 million |
TTM: trailing 12 months
Dividend payout ratio: 90.91% of net profits
Recently Iradimed has paid out, on average, around 90.91% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Iradimed shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Iradimed's case, that would currently equate to about $0 per share.
Iradimed's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Iradimed's most recent dividend payout was on 23 February 2022. The latest dividend was paid out to all shareholders who bought their shares by 15 February 2022 (the "ex-dividend date").
Over the last 12 months, Iradimed's shares have ranged in value from as little as $26 up to $55.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iradimed's is 1.0024. This would suggest that Iradimed's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
